As of April 1, 2024, patients with multiple sclerosis will have access to a new subcutaneous form of natalizumab therapy administration. According to Prof. Monika Adamczyk-Sowa, MD, head of the Department of Neurology in Zabrze at the Silesian Medical University in Katowice, and president of the MS and Neuroimmunology Section of the PTN: "The possibility of subcutaneous therapy is a significant convenience for patients, as it allows for a significant reduction in the time of administration of the drug, and thus the stay in the institution. This improves the overall comfort and quality of life of patients on chronic therapy."
New quality of life for MS patients. Another milestone in the treatment of multiple sclerosis in Poland
Published March 25, 2024 12:29
Today, multiple sclerosis is a very different disease, with a different course and a different prognosis than just a dozen years ago. Thanks to highly effective immunomodulatory drugs, the progression of this disease can be completely halted in most people.
According to the Ministry of Health, natalizumab treatment in subcutaneous form will be available to all patients after intolerance to therapy with natalizumab i.v. (in the intravenous form) due to phlebitis after intravenous infusions or due to difficult venous access.
As Malina Wieczorek, president of the MS-Walcz o siebie Foundation, comments,"We have been striving for a long time to make the new form of therapy available to patients, and we are very pleased that the voice of patients has been heard. This is extending a helping hand not only to patients, but also facilitating the daily work of medical staff and significantly saving time for all parties."
The fact that the patient will spend less time on the medication and in the hospital in general is also not insignificant from a psychological perspective. This seemingly small change can have a dramatic impact on improving a patient's psychological well-being and experience with chronic therapy.
By making another therapy available in MS, the demand of patient organizations and the expert community to allow access within the drug program to all drugs and dosage forms registered in the EU in accordance with the registration indications has thus also been met.
Public perception and messages to a wide range of people, including patients themselves, as well as employers, families and loved ones of people with MS, has been working for 13 years SM-fight for yourself, putting the needs of people living with MS in the spotlight.
"The slogan that says "Patient First" is a very important aspect of our work. Neurology is such a specialty that requires great empathy, all our work revolves around the patient. For me personally, neurology is a lifelong passion, both in terms of medical care, but also in research and teaching. We teach and demonstrate this humility towards neurological diseases. The patient always comes first. - says for the Motivation School portal Prof. Monika Adamczyk-Sowa, MD, head of the Department of Neurology in Zabrze of the Silesian Medical University in Katowice, president of the MS and Neuroimmunology Section of the PTN
Source: press mat.
Topics
stwardnienie rozsiane
